Emicizumab: Review of the literature and critical appraisal, PMID: 30431213
Emicizumab Prophylaxis in Hemophilia A with Inhibitors, PMID: 28691557
Emicizumab, PMID: 32644606
Emicizumab: A Review in Haemophilia A, PMID: 31542880
Emicizumab for hemophilia A without inhibitors, PMID: 31130012
Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A, PMID: 31203578
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors, PMID: 30157389
Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors, PMID: 31746522
Emicizumab treatment and monitoring in a paediatric cohort: real-world data, PMID: 32656767
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors, PMID: 31697801
Emicizumab for the prevention of bleeds in hemophilia A, PMID: 31150297
Emicizumab for the treatment of acquired hemophilia A, PMID: 32766881
Emicizumab-kxwh: First Global Approval, PMID: 29357074
Emicizumab for haemophilia A, PMID: 30765913
Emicizumab, PMID: 31643959
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study, PMID: 31003963
A hemophilia A mouse model for the in vivo assessment of emicizumab function, PMID: 32369559
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study, PMID: 33086400
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors, PMID: 31515851
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial, PMID: 31355677
Evaluating the safety of emicizumab in patients with hemophilia A, PMID: 30462521
Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures, PMID: 32311809
Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals), PMID: 32668090
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?, PMID: 29042366
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors, PMID: 31887777
Emicizumab, PMID: 30000014
Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor, PMID: 33370499
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays, PMID: 31064025
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors, PMID: 30430367
Laboratory issues in gene therapy and emicizumab, PMID: 32469128
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab, PMID: 31033112
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study, PMID: 30427582
Emicizumab for hemophilia A with factor VIII inhibitors, PMID: 30278802
Emicizumab in Hemophilia A, PMID: 32074440
Emicizumab in Hemophilia A, PMID: 32074441
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET, PMID: 31657709
Emicizumab in Hemophilia A. Reply, PMID: 32074442
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens, PMID: 28451690
Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma, PMID: 32892172
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence, PMID: 32547043
Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A, PMID: 33236410
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis, PMID: 32526092
Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A, PMID: 30612605
Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A, PMID: 32588417
Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions, PMID: 32906155
Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII, PMID: 32157756
[Emicizumab: a paradigm shift in hemophilia treatment], PMID: 32507821
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis, PMID: 31373431
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab, PMID: 32237902
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A, PMID: 32717759
Early Emicizumab Treatment in Acquired Hemophilia A: Impact on Bypassing Agent Use and Length of Hospitalization in an Australian Single-Center Cohort., PMID:40527348
Efficacy, safety and satisfaction of using emicizumab in hemophilia A patients without factor VIII inhibitors: A systematic review., PMID:40505240
Implementing an assay detecting anti-drug antibody against emicizumab: experience from one center in France., PMID:40499914
[Hemostatic therapy for hemorrhagic cholecystitis in a patient with hemophilia A with inhibitors]., PMID:40467459
Quantifying Critical Quality Attributes of Protein Therapeutics by Sodium Dodecyl Sulfate-Capillary Gel Electrophoresis With Native Fluorescence Detection., PMID:40448278
A Unique Comparison of Tooth Extraction Before and After Emicizumab Prophylaxis in a Patient With Haemophilia A and Inhibitors., PMID:40444268
In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure., PMID:40398047
Concizumab, a Non-Replacement Therapy for Persons with Hemophilia with Inhibitors., PMID:40363993
Concizumab (Alhemo) for hemophilia A and B with inhibitors., PMID:40324964
In vitro evaluation of global coagulation potential of emicizumab and warfarin using rotational thromboelastometry., PMID:40293607
Emicizumab and Acquired Hemophilia A Secondary to Multiple Myeloma., PMID:40273904
The proportion of young male hemophilia patients who underwent ultrasound examinations: an observational study using a nationwide claims database., PMID:40241164
Impact of Drugs Used in Intensive Care on Routine Coagulation Testing., PMID:40218290
Real-world bleeding rates on emicizumab: the value of using nationwide digital treatment diary data in clinical research., PMID:40206324
Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A., PMID:40199443
Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice., PMID:40176760
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry., PMID:40173026
Clinical Application of Clot Waveform Analysis., PMID:40170405
A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions., PMID:40167950
Five decades of successive establishment of hemophilia care in Thailand., PMID:40159660
Estimation of the budget impact of the dual dispensing circuit of emicizumab in France: The HemiValue study., PMID:40157324
Early diagnosis and prophylactic treatment with emicizumab in premature infants with severe hemophilia A., PMID:40122727
A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres., PMID:40120320
[Application value of thromboelastography in assessing coagulation function in children with severe hemophilia A after emicizumab therapy: a single-center study]., PMID:40105074
Acquired Hemophilia-A Case Series and Review., PMID:40095589
A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors., PMID:40093965
A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis., PMID:40091689
A retrospective single-center study on the effectiveness and tolerability of emicizumab in patients with hemophilia a with and without inhibitors., PMID:40012064
Changes in Hemophilia Treatment in the Eastern Part of Germany between 2015 and 2021-Data from the Kompetenznetz Hämorrhagische Diathese Ost (KHDO)., PMID:39965757
In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds., PMID:39937791
A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors., PMID:39854160
No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy., PMID:39850577
Extending health equity to people with moderate and mild hemophilia A: revisiting the HAVEN 6 trial., PMID:39810986
Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature., PMID:39800259
Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab., PMID:39798924
Dental Considerations in Children with Inherited Bleeding Disorders and Inhibitors: A Systematic Review., PMID:39768665
Marstacimab (Hympavzi) for hemophilia A and B., PMID:39752723
A Prospective, Noninterventional Study to Evaluate the Impact of Emicizumab in the Management of Hemophilia A., PMID:39744287
Low-Dose Emicizumab Versus Low-/Intermediate-Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype., PMID:39737816
HINODE study: haemophilia A in infancy and newborns - protocol for a prospective, multicentre, observational study evaluating the coagulation potential and safety of emicizumab prophylaxis., PMID:39725422
Real-world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center., PMID:39720280
Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis., PMID:39708197
Advances in Development of Drug Treatment for Hemophilia with Inhibitors., PMID:39698264
Systematic review of cost-effectiveness modelling studies for haemophilia., PMID:39693522
Pain-Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies., PMID:39692401
Verification and Implementation of a Bovine Chromogenic Factor VIII Assay for Hemophilia A Patients on Emicizumab Therapy., PMID:39662012
Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary., PMID:39618509
Deconstructing the ISTH hemophilia guidelines for the clinician., PMID:39617189
Non-factor Therapies for Hemophilia: Achievements and Perspectives., PMID:39613145
The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related., PMID:39582123
For research use only. Not for human or drug use.
